Molecular Diagnostics in Cytopathology: Opportunities, Limitations and Pitfalls
Sinchita Roy-Chowdhuri, MD, PhD
MD Anderson Cancer Center
Molecular diagnostics is increasingly being utilized to help guide targeted therapy in solid organ tumors. Increasingly, cytopathologists, are at the forefront of triaging specimens during rapid on-site evaluation and selecting specimens for ancillary testing. Therefore, it is imperative that practicing cytopathologists, stay abreast of up-to-date diagnostic and prognostic ancillary tests utilizing limited cytologic material. This presentation will focus on cytologic substrates for ancillary studies, along with the advantages and disadvantages of each, to help the participants triage and devise optimal strategies for ancillary testing in their own practices.
This educational activity is designed for pathologists, cytopathologists, cytotechnologists, students and other members of the cytopathology community.
- To identify examples of molecular ancillary studies routinely requested on cytologic specimens and be aware of additional techniques likely to be increasingly utilized in the future.
- To provide an overview of the current molecular ancillary studies in the context of cytologic specimens and discuss the basics of ancillary testing with emphasis on analytic sensitivity, how they affect testing, and how best to utilize a specimen to fit a specific molecular ancillary test.
- To compare and contrast different cytologic specimen preparations as well as different molecular technologies and discuss the advantage and disadvantage of each.
- To identify qualitative and quantitative requirements for molecular analysis including pre-analytical variables and devise strategies for implementation of optimal cytologic specimen triage for performing relevant ancillary studies.
Current ACCME guidelines state that participants in CME activities should be made aware of any affiliation or financial interest that may affect the speaker’s presentation(s). Therefore, it is the policy of the ASC to insure balance, independence, objectivity, and scientific rigor in all its educational programs. All planning individuals participating in any ASC Educational Activity are expected to disclose to the program audience any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the continuing education program. Click here for a complete list.
The presenter has no conflicts of interest or financial relationships to disclose.
ACCREDITATION AND DESIGNATION STATEMENTS
Continuing Medical Education (CME) Statement
The American Society of Cytopathology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The American Society of Cytopathology designates this enduring educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
American Board of Pathology Maintenance of Certification (MOC)
This product can help fulfill the CME requirements and Self-Assessment Modules (SAMs) mandated by the American Board of Pathology Maintenance of Certification (MOC) process. Earn up to 2.0 SAM Credit Hours.
Continuing Medical Laboratory Education (CMLE)
The ASC designates this activity for a maximum of 2.0 Continuing Medical Laboratory Education (CMLE) credit hours for non-physicians. The CMLE credit hours meet the continuing education requirements for the ASCP Board of Registry Certification Maintenance Program. Participants should claim only the credit commensurate with the extent of their participation in the activity.
Cytotechnologists with Licenses in Florida and California
This program is approved for 2 continuing education credits in the State of Florida and 1 in the State of California. The credit on each link is good for three years from the live presentation date.
- 2.00 AMA PRA Category 1 Credit™
- 1.00 California Credits
- 2.00 CMLE
- 2.00 Florida Credits
- 2.00 MOC II
- 2.00 Participant